AtheroNova Receives Notice of Issuance of Its 3rd US Patent

IRVINE, Calif., Feb. 13, 2015 /PRNewswire/ -- AtheroNova Inc. (OTCQB: AHRO) today announced that it has received a Notice of Issuance of Patent No. 8952067 titled "Subcutaneous Fat Reduction" by the United States Patent and Trade Office with an expiration date of June 20, 2032.

About AtheroNova
AtheroNova Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, commercialization and licensing of novel prescription compounds and products. For more information, please visit www.AtheroNova.com.

Forward-Looking Statements
This news release includes "forward-looking statements." These statements are based upon the current beliefs and expectations of AtheroNova's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the FDA, general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; AtheroNova's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of AtheroNova's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.  Examples of forward-looking statements in this release include statements regarding the potential commercial value of any issued patents.

AtheroNova undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in AtheroNova's 2013 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atheronova-receives-notice-of-issuance-of-its-3rd-us-patent-300035553.html

SOURCE AtheroNova Inc.

Copyright 2015 PR Newswire